ArticlePloS one2016
Chemical and Antimicrobial Profiling of Propolis from Different Regions within Libya.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Antimicrobial Activity of Ethanolic Propolis Extracts from Tame (Arauca) on Oral Biofilm Co-Cultures.Pathogens (Basel, Switzerland) · 2025Article
- Article
- Therapeutic Potential of Propolis and Royal Jelly in Encephalitozoon Intestinalis Infection: An in Vitro Study.Acta parasitologica · 2025Article
- Molecular Docking and Molecular Dynamics Study of Propolis Compounds of Sulabiroin-A, Sulabiroin-B, and Broussoflavonol F Toward Tuberculosis 3PTY Target Protein.Journal of tropical medicine · 2025Article
- Hive Products: Composition, Pharmacological Properties, and Therapeutic Applications.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The Activity of Red Nigerian Propolis and Some of Its Components againstMolecules (Basel, Switzerland) · 2023Article
- The Antiprotozoal Activity of Papua New Guinea Propolis and Its Triterpenes.Molecules (Basel, Switzerland) · 2022Article
- Pharmaceutical Prospects of Bee Products: Special Focus on Anticancer, Antibacterial, Antiviral, and Antiparasitic Properties.Antibiotics (Basel, Switzerland) · 2021Review
- Activity of Compounds from Temperate Propolis againstMolecules (Basel, Switzerland) · 2021Article
- Antiviral, Antibacterial, Antifungal, and Antiparasitic Properties of Propolis: A Review.Foods (Basel, Switzerland) · 2021Review
- Review
- Promising Anti-Protozoan Activities of Propolis (Bee Glue) as Natural Product: A Review.Acta parasitologica · 2021Review
- Antitrypanosomal and Antileishmanial Activity of Chalcones and Flavanones fromPathogens (Basel, Switzerland) · 2021Article
- Review
- Article
- Biomedical Properties of Propolis on Diverse Chronic Diseases and Its Potential Applications and Health Benefits.Nutrients · 2020Review
- Novel flavanones with anti-trypanosomal activity isolated from Zambian and Tanzanian propolis samples.International journal for parasitology. Drugs and drug resistance · 2020Article
- The Strong Anti-Kinetoplastid Properties of Bee Propolis: Composition and Identification of the Active Agents and Their Biochemical Targets.Molecules (Basel, Switzerland) · 2020Review
- Comprehensive multivariate correlations between climatic effect, metabolite-profile, antioxidant capacity and antibacterial activity of Brazilian red propolis metabolites during seasonal study.Scientific reports · 2019Article
- Investigation of 5'-Norcarbocyclic Nucleoside Analogues as Antiprotozoal and Antibacterial Agents.Molecules (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracts from twelve samples of propolis collected from different regions of Libya were tested for their activity against Trypanosoma brucei, Leishmania donovani, Plasmodium falciparum, Crithidia fasciculata and Mycobacterium marinum and the cytotoxicity of the extracts was tested against mammalian cells. All the extracts were active to some degree against all of the protozoa and the mycobacterium, exhibiting a range of EC50 values between 1.65 and 53.6 μg/ml. The toxicity against mammalian cell lines was only moderate; the most active extract against the protozoan species, P2, displayed an IC50 value of 53.2 μg/ml. The extracts were profiled by using liquid chromatography coupled to high resolution mass spectrometry. The data sets were extracted using m/z Mine and the accurate masses of the features extracted were searched against the Dictionary of Natural Products (DNP). A principal component analysis (PCA) model was constructed which, in combination with hierarchical cluster analysis (HCA), divided the samples into five groups. The outlying groups had different sets of dominant compounds in the extracts, which could be characterised by their elemental composition. Orthogonal partial least squares (OPLS) analysis was used to link the activity of each extract against the different micro-organisms to particular components in the extracts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.